Drugs for diabetes: part 6 GLP-1 receptor agonists

Br J Cardiol 2011;18:167–69 Leave a comment
Click any image to enlarge
Authors:

The glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the treatment of type 2 diabetes. They mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin. They have additional effects in reducing glucagon, slowing gastric emptying, and inducing satiety. In clinical practice they are associated with significant reductions in glycosylated haemoglobin (HbA1c), weight loss and a low risk of hypoglycaemia. Beneficial effects have also been observed on blood pressure and lipids. The possibility of cardiovascular benefit is now being formally examined in large randomised-controlled trials with primary cardiovascular end points.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT